We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals
BMRN

547 hedge funds and large institutions have $18B invested in BioMarin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 178 increasing their positions, 207 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 85 | Existing positions closed: 50

36% more call options, than puts

Call options by funds: $193M | Put options by funds: $141M

12% more capital invested

Capital invested by funds: $16.1B → $18B (+$1.96B)

5% more funds holding

Funds holding: 519 → 547 (+28)

2.79% more ownership

Funds ownership: 96.45% → 99.24% (+2.8%)

0% more funds holding in top 10

Funds holding in top 10: 14 → 14 (0)

14% less repeat investments, than reductions

Existing positions increased: 178 | Existing positions reduced: 207

Holders
547
Holders Change
+28
Holders Change %
+5.39%
% of All Funds
7.97%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.2%
New
85
Increased
178
Reduced
207
Closed
50
Calls
$193M
Puts
$141M
Net Calls
+$51.4M
Net Calls Change
-$924K

Top Buyers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
+$421M
2
EIM
Elliott Investment Management
Florida
+$265M
3
Deutsche Bank
Deutsche Bank
Germany
+$177M
4
Morgan Stanley
Morgan Stanley
New York
+$99M
5
Millennium Management
Millennium Management
New York
+$80M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$337M
2
Nomura Holdings
Nomura Holdings
Japan
-$62.6M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$56.1M
4
Pictet Asset Management
Pictet Asset Management
Switzerland
-$44.7M
5
PHS
PFM Health Sciences
California
-$44.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
ECM
551
ExodusPoint Capital Management
New York
– -$15M -170,017 Closed
EAM
552
Eventide Asset Management
Massachusetts
– -$14.5M -164,299 Closed
HA
553
HHLR Advisors
Cayman Islands
– -$10.1M -114,042 Closed
TI
554
Trexquant Investment
Connecticut
– -$5.45M -61,605 Closed
WG
555
Winton Group
United Kingdom
– -$1.83M -20,712 Closed
SC
556
Sculptor Capital
New York
– -$1.66M -18,799 Closed
DFCM
557
Dark Forest Capital Management
Puerto Rico
– -$1.54M -17,388 Closed
SPA
558
Sherbrooke Park Advisers
New York
– -$1.11M -12,515 Closed
Federated Hermes
559
Federated Hermes
Pennsylvania
– -$1.01M -11,382 Closed
CP
560
CenterBook Partners
Connecticut
– -$932K -10,534 Closed
SCM
561
Silverarc Capital Management
Massachusetts
– -$885K -10,000 Closed
BSA
562
Braun Stacey Associates
New York
– -$863K -9,750 Closed
AIM
563
Aigen Investment Management
New York
– -$769K -8,691 Closed
Group One Trading
564
Group One Trading
Illinois
– -$714K -8,073 Closed
WP
565
Waycross Partners
Kentucky
– -$619K -7,000 Closed
GCP
566
GSA Capital Partners
United Kingdom
– -$564K -6,373 Closed
MNBTD
567
Moody National Bank Trust Division
Texas
– -$509K -5,752 Closed
Connor, Clark & Lunn Investment Management (CC&L)
568
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$468K -5,292 Closed
AG
569
Algert Global
California
– -$459K -5,186 Closed
SG Americas Securities
570
SG Americas Securities
New York
– -$439K -4,957 Closed
IIM
571
Intact Investment Management
Quebec, Canada
– -$425K -4,800 Closed
CHP
572
Cable Hill Partners
Oregon
– -$386K -4,361 Closed
AI
573
Atom Investors
Texas
– -$367K -4,145 Closed
MM
574
MQS Management
New York
– -$355K -4,015 Closed
ALAM
575
Asahi Life Asset Management
Japan
– -$310K -3,500 Closed
20 21 22
23
24

BMRN Hedge Fund Activity: Q4 2023 in Review

547 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2023, worth a combined $18B — up 12% from $16.1B a quarter earlier.

Buyers outnumbered sellers: 85 funds opened new BMRN positions and 50 closed out — a net gain of 35 holders — while 178 added to existing stakes and 207 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $421M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $337M sold.

  • 547 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2023, up from 519 in Q3 2023.
  • Funds reported $18B of BioMarin Pharmaceuticals stock for Q4 2023, up 12% quarter-over-quarter.
  • 85 funds opened new BioMarin Pharmaceuticals positions in Q4 2023 and 50 closed out, a net change of +35 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2023 was Capital Research Global Investors, an estimated $421M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2023 was Baker Bros. Advisors, an estimated $337M sold.

Based on aggregated 13F filings for Q4 2023.